In biomanufacturing, purifying a product is a major cost. Using an organism that secretes the product directly into the media eliminates the need for cell lysis and reduces endotoxin concerns. This simplification of downstream processing can cut total production costs by 25-33%, a significant competitive advantage.
Unlike traditional fermentation where moving to larger tanks introduces significant process variability, photosynthetic systems using photobioreactors scale modularly. Companies can simply add more units ("scaling out"), which minimizes performance differences and de-risks the transition to commercial-scale manufacturing.
For consumer industries like personal care, an ingredient's origin story is a key differentiator. By using an ocean-based strain, a company can create a unique "ocean-derived" marketing claim, justifying premium pricing and capturing consumer interest beyond just its sustainability benefits.
For over a decade, slow growth rates and poor yields made cyanobacteria commercially unfeasible. The recent discovery of a faster-growing strain, combined with new genetic modification tools, has finally unlocked its industrial potential, closing the efficiency gap with established microbes like E. coli.
Instead of pursuing high-impact but low-margin commodities like biofuels, new biotech platforms should first target high-priced niche markets like cosmetics. This strategy generates revenue faster with "good enough" technology, funding the R&D required to eventually compete in cost-sensitive commodity markets.